To say the Hep C space is crowded would be an understatement.
The HCV space is crowded but it is not unduly crowded, IMO. There is no other serious and common medical condition where the business opportunity is as compelling for a major advance in the standard of care during the next 5-10 years.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”